Rk Capital Management, LLC Ligand Pharmaceuticals Inc Transaction History

Rk Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 14, 2019	SELL	$105.93 - $142.47 $10 Million - $13.5 Million	-94,583 Closed	0 $0
Q4 2018 Feb 13, 2019	BUY	$128.36 - $272.13 $8.27 Million - $17.5 Million	64,400 Added 213.37%	94,583 $12.8 Million
Q3 2018 Nov 13, 2018	SELL	$211.18 - $274.49 $4.41 Million - $5.74 Million	-20,900 Reduced 40.91%	30,183 $8.29 Million
Q2 2018 Aug 13, 2018	BUY	$150.77 - $207.98 $437,233 - $603,142	2,900 Added 6.02%	51,083 $10.6 Million
Q1 2018 May 14, 2018	BUY	$138.63 - $182.62 $1.3 Million - $1.72 Million	9,400 Added 24.24%	48,183 $7.96 Million
Q4 2017 Feb 13, 2018	SELL	$128.36 - $147.04 $5.89 Million - $6.75 Million	-45,900 Reduced 54.2%	38,783 $5.31 Million
Q3 2017 Nov 13, 2017	BUY	$120.91 - $137.94 $10.2 Million - $11.7 Million	84,683	84,683 $11.5 Million

257

18.2M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.88B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Rk Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rk Capital Management, LLC with notifications on news.